Drug search by name

Peginterferon Alfa-2b (Peg-Intron) and Myelosuppression

Result of checking the interaction of drug Peginterferon Alfa-2b (Peg-Intron) and disease Myelosuppression for safety when used together.

Check result:

Peginterferon Alfa-2b (Peg-Intron) <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.

References:

"Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
"Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.

Peginterferon Alfa-2b (Peg-Intron)

Generic Name: peginterferon alfa-2b

Brand Name: PegIntron, Sylatron, PegIntron Redipen

Synonyms: Peginterferon alfa-2b, Peginterferon Alfa-2b

What is Peginterferon Alfa-2b (Peg-Intron)?